Is guided by advanced laboratory analysis and precision-based care, focusing on individualized molecular patterns rather than a one-size-fits-all strategy.
We use advanced laboratory analysis to identify:
This allows for a precision-guided approach based on your unique data — not guesswork.
Your protocol is developed based on your individual laboratory findings and clinical picture, and may include:
Each plan is individualized and adjusted over time based on response, tolerance, and ongoing evaluation.
Q-REstrain is integrated within a broader care approach designed to support overall physiological function and treatment readiness. This may include:
This ensures the body is supported throughout care.
Q-REstrain care is guided by continuous evaluation and thoughtful adjustments based on your clinical response and evolving needs.
Our goal is to provide consistent, individualized support — with a focus on stability, resilience, and long-term alignment.
Indigo Health Clinic was founded with one purpose: to give patients the kind of care we wish we had when we were searching for answers.
Our practice is built on compassion, curiosity, and the belief that healing happens when you’re truly seen, heard, and supported. Our integrative team looks beyond symptoms to understand the full picture — your history, lifestyle, environment, labs, and unique physiology.
At Indigo, you’ll find:

The Indigo Promise
Our Q-REstrain therapy is designed for patients seeking clarity, individualized support, and a data-guided approach to complex conditions. We may be a fit if you:

Commonly Asked Questions
If you’re exploring Q-REstrain, you may have questions about how it works, what to expect, and whether it’s right for you. Here are the most common ones.
Q-REstrain (formerly Supportive Oligonucleotide Therapy, or SOT) is a laboratory-guided, adjunctive support therapy designed to target specific molecular signals expressed by cancer cells.
Q-REstrain is used as supportive care and is never a replacement for conventional oncology treatment.
No. Q-REstrain does not diagnose, treat, or cure cancer. It is an adjunctive therapy intended to support the body alongside standard oncology care under careful clinical oversight.
Q-REstrain uses highly specific oligonucleotides designed to interact with molecular targets identified through advanced laboratory testing, such as RGCC analysis. The goal is precision support based on individualized tumor signaling rather than one-size-fits-all approaches.
Q-REstrain may be considered for select patients based on:
- RGCC or equivalent molecular testing results
- Cancer type and current treatment plan
- Overall clinical stability
- Oncology coordination and approval
- Lyme patients with multiple co-infections
Not all patients are appropriate candidates. Careful screening and laboratory confirmation are required.
When appropriately selected and administered, Q-REstrain can be safe. Safety depends on:
- Laboratory confirmation of target suitability
- Conservative dosing and administration protocols
- Timing relative to oncology treatment
- Ongoing clinical monitoring
We proceed only when safety parameters are clearly met and coordination with the oncology team is in place.
As an adjunctive approach, Q-REstrain may help support:
- Precision-aligned treatment strategies
- Reduced reliance on non-specific supportive approaches
- Improved alignment between laboratory data and care decisions
Individual responses vary. Outcomes are monitored clinically and, when appropriate, through follow-up testing.
As with any biologically active therapy, potential risks exist. Side-effects vary by individual and clinical context. All known risks, limitations, and expectations are reviewed in detail prior to proceeding.
Q-REstrain protocols are individualized based on:
- Molecular testing results (e.g., RGCC analysis)
- Medical history and diagnosis
- Current oncology treatments
- Laboratory markers and clinical tolerance
- Patient goals and preferences
Care plans are adjusted as treatment and clinical status evolve.
Our approach emphasizes:
- Adjunctive, data-informed care
- Precision over generalized protocols
- Conservative, safety-first decision-making
- Clear boundaries with oncology-directed treatment
- Ongoing reassessment as clinical needs change
We prioritize clarity, coordination, and clinical appropriateness.
Q-REstrain is a laboratory-guided, supportive therapy designed to target specific molecular signals associated with Lyme and co-infections. It may help support the body’s response to persistent infections and is used as part of an individualized, provider-guided care plan.
Important:
Q-REstrain is not considered a standalone cure or first-line treatment for Lyme disease. It is used as a supportive, individualized therapy within a broader clinical strategy, based on laboratory findings and provider oversight.
A free Discovery Call allows us to review your health concerns to determine whether Q-REstrain may be appropriate for you. If so, we’ll take care of scheduling the appropriate Initial Consultation to ensure thorough evaluation, coordination, and thoughtful planning before initiation.
We Can Help!
Every day you delay is another day lost to fatigue, pain, and uncertainty. Take the first step toward lasting recovery and claim your free consultation today.